MCID: SVR005
MIFTS: 56

Severe Pre-Eclampsia

Categories: Blood diseases, Cardiovascular diseases, Nephrological diseases, Rare diseases, Reproductive diseases, Respiratory diseases

Aliases & Classifications for Severe Pre-Eclampsia

MalaCards integrated aliases for Severe Pre-Eclampsia:

Name: Severe Pre-Eclampsia 12 55 15 73
Severe Preeclampsia 12 15
Severe Pre-Eclampsia, Antepartum Condition or Complication 73
Severe Pre-Eclampsia, Postpartum Condition or Complication 73
Severe Pre-Eclampsia, with Delivery 12
Antepartum Severe Pre-Eclampsia 12
Postpartum Severe Pre-Eclampsia 12
Severe Toxemia 73

Classifications:



External Ids:

Disease Ontology 12 DOID:13129
ICD9CM 35 642.50
ICD10 33 O14.1

Summaries for Severe Pre-Eclampsia

Disease Ontology : 12 A pre-eclampsia that has symptom at least one of the following

MalaCards based summary : Severe Pre-Eclampsia, also known as severe preeclampsia, is related to hellp syndrome and antiphospholipid syndrome. An important gene associated with Severe Pre-Eclampsia is HLA-G (Major Histocompatibility Complex, Class I, G), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Fluid shear stress and atherosclerosis. The drugs Methyldopa and Magnesium Sulfate have been mentioned in the context of this disorder. Affiliated tissues include placenta, liver and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Severe Pre-Eclampsia

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Severe Pre-Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 179)
# Related Disease Score Top Affiliating Genes
1 hellp syndrome 31.7 APOH F5 LGALS13 PGF SERPINC1
2 antiphospholipid syndrome 31.5 APOH F5 SERPINC1 VCAM1
3 eclampsia 31.5 ALB HLA-G LGALS13 PGF SERPINC1
4 pre-eclampsia 30.6 ADIPOQ APOH F5 HLA-G LEP LEPR
5 gestational diabetes 30.0 ADIPOQ LEP RBP4
6 placental insufficiency 29.9 FGR LEP PGF VEGFA
7 fatty liver disease 29.6 ADIPOQ LEP LEPR
8 thrombophilia 29.5 APOH F5 SERPINC1
9 placental abruption 29.4 APOH F5 PGF SERPINC1
10 thrombosis 29.4 APOH F5 SERPINC1
11 endocarditis 29.4 ALB APOH SERPINC1 VCAM1
12 antithrombin iii deficiency 29.2 APOH F5 SERPINC1
13 protein s deficiency 29.2 APOH F5 SERPINC1
14 ischemic optic neuropathy 29.2 APOH F5 SERPINC1
15 budd-chiari syndrome 29.2 APOH F5 SERPINC1
16 thrombophilia due to thrombin defect 29.2 APOH F5 SERPINC1
17 preeclampsia/eclampsia 1 11.0
18 severe nonproliferative diabetic retinopathy 10.2 ALB VEGFA
19 angiokeratoma circumscriptum 10.2 MMP9 VEGFA
20 sick building syndrome 10.2 LEP MMP9 VEGFA
21 obesity-hypoventilation syndrome 10.2 ADIPOQ LEP
22 acroosteolysis 10.2 ALB VEGFA
23 idiopathic recurrent pericarditis 10.2 ADIPOQ LEP
24 trypanosomiasis 10.2 ALB HLA-G VCAM1
25 adamantinous craniopharyngioma 10.2 MMP9 VEGFA
26 lipoblastoma 10.2 LEP LEPR
27 brain edema 10.2 ALB MMP9 VEGFA
28 hydatidiform mole, recurrent, 1 10.2
29 hemolytic anemia 10.2
30 pulmonary edema 10.2
31 gestational trophoblastic neoplasm 10.2
32 microvascular complications of diabetes 1 10.2 MMP9 VCAM1 VEGFA
33 balanitis xerotica obliterans 10.2 APLN VEGFA
34 respiratory system disease 10.1 ALB MMP9 VEGFA
35 gastrointestinal system cancer 10.1 ALB MMP9 VEGFA
36 coronary artery aneurysm 10.1 ADIPOQ LEP VCAM1
37 parotitis 10.1 ALB MMP9
38 prediabetes syndrome 10.1 ADIPOQ ALB LEP
39 endocrine gland cancer 10.1 ALB MMP9 VEGFA
40 gastrointestinal system disease 10.1 ALB MMP9 VEGFA
41 glucose metabolism disease 10.1 ADIPOQ ALB LEP
42 mild pre-eclampsia 10.1 LEP PGF VCAM1
43 fournier gangrene 10.1 ALB SERPINC1
44 nervous system disease 10.1 ALB MMP9 VEGFA
45 retinal vascular disease 10.1 ALB PGF VEGFA
46 lipid metabolism disorder 10.1 ADIPOQ LEP RBP4
47 eating disorder 10.1 ADIPOQ LEP LEPR
48 sleep apnea 10.1 ADIPOQ LEP LEPR
49 overnutrition 10.1 ADIPOQ LEP LEPR
50 hypertension, essential 10.1

Graphical network of the top 20 diseases related to Severe Pre-Eclampsia:



Diseases related to Severe Pre-Eclampsia

Symptoms & Phenotypes for Severe Pre-Eclampsia

MGI Mouse Phenotypes related to Severe Pre-Eclampsia:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.34 ADIPOQ APLN F5 FGR HIF1AN LEP
2 homeostasis/metabolism MP:0005376 10.33 ADIPOQ ALB APLN APOH F5 HIF1AN
3 growth/size/body region MP:0005378 10.19 ADIPOQ APLN F5 HIF1AN LEP LEPR
4 hematopoietic system MP:0005397 10.13 ADIPOQ FGR HLA-G LEP LEPR MMP9
5 immune system MP:0005387 10.13 ADIPOQ FGR HLA-G LEP LEPR MMP9
6 embryo MP:0005380 10.11 APLN F5 LEP LEPR PGF SERPINC1
7 liver/biliary system MP:0005370 9.97 ADIPOQ ALB F5 HIF1AN LEP LEPR
8 muscle MP:0005369 9.97 ADIPOQ ALB APLN HIF1AN LEP LEPR
9 integument MP:0010771 9.95 ADIPOQ F5 LEP LEPR MMP9 PGF
10 neoplasm MP:0002006 9.8 ADIPOQ ALB LEP LEPR MMP9 PGF
11 renal/urinary system MP:0005367 9.76 ADIPOQ ALB LEP LEPR MMP9 RBP4
12 respiratory system MP:0005388 9.5 ADIPOQ HIF1AN LEP LEPR MMP9 PGF
13 vision/eye MP:0005391 9.23 APLN LEP LEPR MMP9 PGF RBP4

Drugs & Therapeutics for Severe Pre-Eclampsia

Drugs for Severe Pre-Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 218)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyldopa Approved Phase 4 555-30-6 38853
2
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 7487-88-9 24083
3
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
4
Clonidine Approved Phase 4 4205-90-7 2803
5
Captopril Approved Phase 4 62571-86-2 44093
6
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2 9005-49-6 772 46507594
7
Enoxaparin Approved Phase 4,Phase 3,Not Applicable 9005-49-6 772
8
Dalteparin Approved Phase 4,Phase 3 9005-49-6
9
leucovorin Approved Phase 4,Phase 3 58-05-9 6006 143
10
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-78-2 2244
11
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
12
rituximab Approved Phase 4 174722-31-7 10201696
13
Labetalol Approved Phase 4,Phase 2,Phase 3 36894-69-6 3869
14
Ibuprofen Approved Phase 4,Phase 2,Phase 3 15687-27-1 3672
15
Acetaminophen Approved Phase 4,Phase 2,Phase 3 103-90-2 1983
16
Warfarin Approved Phase 4 81-81-2 6691 54678486
17
Nifedipine Approved Phase 4,Phase 2,Phase 3 21829-25-4 4485
18
Benzocaine Approved, Investigational Phase 4,Phase 3 94-09-7, 1994-09-7 2337
19 tannic acid Approved Phase 4,Phase 3
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
21 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Not Applicable
22 Anesthetics Phase 4,Phase 2,Phase 3,Not Applicable
23 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Not Applicable
24 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Antibodies, Antiphospholipid Phase 4
26 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Anticoagulants Phase 4,Phase 3,Phase 2
28 Antibodies Phase 4,Phase 2,Phase 3
29 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Immunologic Factors Phase 4,Phase 2,Phase 3
31 Immunoglobulins Phase 4,Phase 2,Phase 3
32 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Antimetabolites Phase 4,Phase 1,Phase 2
34 Tocolytic Agents Phase 4,Phase 2,Phase 3,Not Applicable
35 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 3,Not Applicable
36 calcium channel blockers Phase 4,Phase 2,Phase 3,Not Applicable
37 Analgesics Phase 4,Phase 2,Phase 3,Not Applicable
38 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Anticonvulsants Phase 4,Phase 2,Phase 3,Not Applicable
40 Pharmaceutical Solutions Phase 4,Phase 3,Not Applicable
41 diuretics Phase 4
42 Sodium Potassium Chloride Symporter Inhibitors Phase 4
43 Natriuretic Agents Phase 4
44 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2
45
protease inhibitors Phase 4
46 Adrenergic Agonists Phase 4,Phase 3,Phase 2
47 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
48 Sympatholytics Phase 4
49 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
50 Adrenergic Agents Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 129)
# Name Status NCT ID Phase Drugs
1 Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape) Unknown status NCT01361425 Phase 4 methildopa;placebo
2 Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia Completed NCT01408979 Phase 4 Magnesium sulfate 12 hours;Magnesium sulfate 24 hours
3 A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen Completed NCT02091401 Phase 4 Magnesium Sulfate
4 Diuretics for Postpartum High Blood Pressure in Preeclampsia Completed NCT02163655 Phase 4 FUROSEMIDE;Placebo
5 Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure Completed NCT01761916 Phase 4 CLONIDINE;CAPTOPRIL
6 Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
7 Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias Completed NCT02761174 Phase 4 Brimonidine
8 Timing of Initiation of LMWH Administration in Pregnant Women With APS Completed NCT02326051 Phase 4 Enoxaparin;Enoxaparin
9 Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers Completed NCT01729468 Phase 4 Aspirin;Placebo
10 A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis. Completed NCT00502853 Phase 4 rituximab [MabThera/Rituxan];Methotrexate
11 Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia Recruiting NCT03164304 Phase 4 Magnesium Sulfate
12 Use of Warfarin After the First Trimester in Pregnant Women With APS Recruiting NCT02303171 Phase 4 Enoxaparin;Warfarin
13 Chronic Hypertension and Pregnancy (CHAP) Project Recruiting NCT02299414 Phase 4 Anti-hypertensive therapy
14 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Active, not recruiting NCT02911701 Phase 4 Acetaminophen;Ibuprofen
15 Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Not yet recruiting NCT03318211 Phase 4 Magnesium Sulfate
16 Different Schemes of Magnesium Sulfate for Preeclampsia Terminated NCT02396030 Phase 4 Magnesium sulfate 50% - 1g/h;Magnesium sulfate 50% - 2g/h
17 Atenativ Effect on Uterine Blood Flow and Preeclampsia Withdrawn NCT02278575 Phase 4 Atenativ
18 Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe Preeclampsia Unknown status NCT01382732 Phase 3 Carbetocin;Oxytocin
19 Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia Using Carbetocin Versus Misoprostol Completed NCT02086994 Phase 3 misoprostol;carbetocin
20 Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia Completed NCT02307201 Phase 2, Phase 3 Magnesium Sulfate
21 Prevention of Maternal and Perinatal Complications by Enoxaparin in Women With Previous Severe Preeclampsia Completed NCT00986765 Phase 3 Lovenox® (enoxaparin);Aspegic ® (Aspirin)
22 Magnesium Sulfate in Pregnancy and Postpartum Completed NCT02317146 Phase 2, Phase 3 Magnesium Sulfate
23 Nonsteroidal Antiinflammatory Drugs in Women With Postpartum Pre-eclampsia Completed NCT01988298 Phase 2, Phase 3 Ibuprofen;Acetaminophen
24 New Magnesium Sulphate Protocol for Pre-eclampsia Completed NCT01846156 Phase 3 MgSO4
25 Antioxidant Supplementation in Pregnant Women Completed NCT01232205 Phase 2, Phase 3
26 A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations Completed NCT00857454 Phase 3 Testosterone MD-Lotion
27 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention Completed NCT01355159 Phase 3 Folic Acid 4 mg;Placebo
28 A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations Completed NCT00702650 Phase 3 Testosterone MD-Lotion
29 Oral Nifedipine Versus IV Labetalol in Severe Pre Eclampsia Recruiting NCT03325348 Phase 2, Phase 3 Nifedipine 10 mg;Labetalol
30 Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia Recruiting NCT03008616 Phase 2, Phase 3
31 The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine Recruiting NCT02558023 Phase 3 Urapidil;Nicardipine
32 Use of Sildenafil Citrate in Management of Mild Pre-eclampsia Recruiting NCT03262961 Phase 2, Phase 3 Sildenafil 20 MG;Placebo Oral Tablet
33 Magnesium Sulphate for Preterm Birth (MASP Study) Active, not recruiting NCT01492608 Phase 3 Magnesium sulphate
34 Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care Not yet recruiting NCT03237819 Phase 3 Sulfate, Magnesium;Placebo - Concentrate
35 Prevention of Preeclampsia With Aspirin in Recipients of Donated Oocytes. Suspended NCT02174328 Phase 3 Acetylsalicylic acid;Placebo
36 Maternal and Neonatal Outcomes of the Use of Vasopressors to Treat Hypotension During Spinal Anesthesia for Cesarean Withdrawn NCT01451060 Phase 3 Metaraminol;Ephedrine
37 Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery Withdrawn NCT01796522 Phase 3 progesterone 200 mg / day vaginally;nifedipine (60 mg / day orally)
38 Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial Withdrawn NCT00293735 Phase 2, Phase 3 labetalol (seizure prevention);MgSO4 (seizure prevention)
39 Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery Unknown status NCT02314286 Phase 1, Phase 2 Rosuvastatin;Placebo
40 Should Colon or Non-colon Originated Lesions be Distinguished? Unknown status NCT02939508 Phase 1, Phase 2
41 Efficacy Study of Digibind for Treatment of Severe Preeclampsia Completed NCT00158743 Phase 2 Anti-digoxin antibody (FAB fragment)
42 Dexmedetomidine vs. Remifentanil for Pre-eclampsia During Caesarean Delivery Completed NCT01766089 Phase 2 Remifentanil;Dexmedetomidine
43 Safety and Acceptability of a Vaginal Microbicide Completed NCT00111943 Phase 2 1% tenofovir gel
44 Aspirin for the Enhancement of Trophoblastic Invasion in Women With Abnormal Uterine Artery Doppler at 11-14 Weeks of Gestation Completed NCT01616615 Phase 2 Aspirin;placebo
45 Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System Completed NCT00916383 Phase 2 350 mg Donepezil Transdermal Patch;Placebo Patch
46 A Study for the Transdermal Application of Teriparatide Completed NCT01011556 Phase 2 Subcutaneous Teriparatide;Transdermal Teriparatide
47 Indonesia Pravastatin to Prevent Preeclampsia Study Recruiting NCT03648970 Phase 2 Pravastatin
48 IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy Recruiting NCT03152058 Phase 2 Certolizumab Pegol
49 Usefulness of Extracorporeal Removal of sFLT-1 in Women With Very Early Severe Preeclampsia Terminated NCT02286284 Phase 2
50 Clinical Trial of a COX-2 Inhibitor for the Treatment of Women With Preeclampsia Withdrawn NCT00442676 Phase 2 Celecoxib;Placebo

Search NIH Clinical Center for Severe Pre-Eclampsia

Genetic Tests for Severe Pre-Eclampsia

Anatomical Context for Severe Pre-Eclampsia

MalaCards organs/tissues related to Severe Pre-Eclampsia:

41
Placenta, Liver, Endothelial, Lung, Skin, Kidney, Testes

Publications for Severe Pre-Eclampsia

Articles related to Severe Pre-Eclampsia:

(show top 50) (show all 839)
# Title Authors Year
1
Maternal cardiac output response to colloid preload and vasopressor therapy during spinal anaesthesia for caesarean section in patients with severe pre-eclampsia: a randomised, controlled trial. ( 29086911 )
2018
2
Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy. ( 29789925 )
2018
3
A case of partial hydatidiform molar pregnancy with a placental diploid-triploid mosaicism associated with a euploid viable foetus complicated with severe pre-eclampsia. ( 29421928 )
2018
4
Baseline check of blood pressure readings of an automated device in severe pre-eclampsia and healthy normotensive pregnancy. ( 29674198 )
2018
5
Molar pregnancy with normal viable fetus presenting with severe pre-eclampsia: a case report. ( 29779493 )
2018
6
Severe pre-eclampsia among pregnant women with sickle cell disease and HIV. ( 29523281 )
2018
7
Severe Preeclampsia, Antiphospholipid Syndrome, and Ulnar Artery Thrombosis in a Teenage Pregnancy: A Rare Association. ( 30319825 )
2018
8
Hypertension, Anxiety, and Blood-Brain Barrier Permeability Are Increased in Postpartum Severe Preeclampsia/Hemolysis, Elevated Liver Enzymes, and Low Platelet Count Syndrome Rats. ( 30354708 )
2018
9
Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation. ( 30289565 )
2018
10
Renalase rs10887800 polymorphism is associated with severe pre-eclampsia in southeast Iranian women. ( 30304564 )
2018
11
Prognostic accuracy of cerebroplacental ratio for adverse perinatal outcomes in pregnancies complicated with severe pre-eclampsia; a prospective cohort study. ( 30527124 )
2018
12
Neuroimaging findings in women who develop neurologic symptoms in severe preeclampsia with or without eclampsia. ( 29808032 )
2018
13
Prophylactic magnesium sulphate in prevention of eclampsia in women with severe preeclampsia: randomised controlled trial (PIPES trial). ( 28974124 )
2018
14
Extra-adrenal paraganglioma masquerading as severe preeclampsia. ( 30018907 )
2018
15
Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: a case-control study. ( 30028257 )
2018
16
Multidisciplinary team approach for an atypical presentation of postpartum thrombotic thrombocytopenic purpura and severe preeclampsia in the Intensive Care Unit. ( 30429751 )
2018
17
Can thrombophilia worsen maternal and perinatal outcomes in cases of severe preeclampsia? ( 29523280 )
2018
18
Optic nerve ultrasound for fluid status assessment in patients with severe preeclampsia. ( 30511937 )
2018
19
Point-of-Care Ultrasound Abnormalities in Late-Onset Severe Preeclampsia: Prevalence and Association With Serum Albumin and Brain Natriuretic Peptide. ( 30211771 )
2018
20
Use of a qualitative case study to learn lessons from severe preeclampsia causing a maternal near-miss: a case report. ( 30253802 )
2018
21
Ocular perfusion pressure and intraocular pressure in pregnant women with severe preeclampsia. ( 30318579 )
2018
22
LDL-apheresis to decrease sFlt-1 during early severe preeclampsia: Report of two cases from a discontinued phase II trial. ( 30326377 )
2018
23
Circulating Heme Oxygenase-1: Not a Predictor of Preeclampsia but Highly Expressed in Pregnant Women Who Subsequently Develop Severe Preeclampsia. ( 30363976 )
2018
24
Elevated HTRA1 and HTRA4 in severe preeclampsia and their roles in trophoblast functions. ( 30015931 )
2018
25
Reply to: Acute kidney injury in parturients with severe preeclampsia. ( 30043101 )
2018
26
Acute kidney injury in parturients with severe preeclampsia. ( 30043102 )
2018
27
Ocular ultrasonography for diagnosing increased intracranial pressure in patients with severe preeclampsia. ( 30057149 )
2018
28
Reply to Liu et al.: Decidualization defect in severe preeclampsia. ( 30068606 )
2018
29
Mode of Delivery in Severe Preeclampsia Before 28 Weeks' Gestation: A Systematic Review. ( 30169885 )
2018
30
Plasma levels of TAM receptors and ligands in severe preeclampsia. ( 30177037 )
2018
31
Effects of compound Danshen injection combined with magnesium sulfate on serum MPO and hs-CRP in patients with severe preeclampsia. ( 29896236 )
2018
32
Role of endogenous digitalis-like factors in the clinical manifestations of severe preeclampsia: a sytematic review. ( 29930141 )
2018
33
A randomized trial comparing the pharmacology of magnesium sulfate when used to treat severe preeclampsia with serial intravenous boluses versus a continuous intravenous infusion. ( 29976161 )
2018
34
Adverse Maternal Outcomes Differ between Obese and Nonobese Women with Severe Preeclampsia. ( 29980156 )
2018
35
Expression of urotensin II is associated with placental autophagy in patients with severe preeclampsia. ( 29991702 )
2018
36
Management of pregnancy and emergency caesarean delivery in a patient with type IIB von Willebrand disease and severe preeclampsia: A case report and literature review. ( 29997693 )
2018
37
Wnt/β-catenin signaling pathway in severe preeclampsia. ( 29603045 )
2018
38
Angiogenic Factor Profiles in Pregnant Women With a History of Early-Onset Severe Preeclampsia Receiving Low-Molecular-Weight Heparin Prophylaxis. ( 29683898 )
2018
39
Serum and Urine Thioflavin-T-Enhanced Fluorescence in Severe Preeclampsia. ( 29686018 )
2018
40
Oxidative stress markers and thrombomodulin plasma levels in women with early and late severe preeclampsia. ( 29723511 )
2018
41
Postoperative renal function in parturients with severe preeclampsia who underwent cesarean delivery: a retrospective observational study. ( 29728756 )
2018
42
A tag SNP in syncytin-2 3-UTR significantly correlates with the risk of severe preeclampsia. ( 29750965 )
2018
43
Abnormal lymphatic vessel development is associated with decreased decidual regulatory T cells in severe preeclampsia. ( 29756666 )
2018
44
Ultrasound assessment of visual loss during severe preeclampsia: a case report. ( 29435677 )
2018
45
Blood Pressure Profile 1 Year After Severe Preeclampsia. ( 29437895 )
2018
46
Maternal serum AMP-activated protein kinase levels in mild and severe preeclampsia. ( 29504441 )
2018
47
Comparison of the effects of low doses of dexmedetomidine and remifentanil on the maternal hemodynamic changes during caesarean delivery in patients with severe preeclampsia: a randomized trial. ( 29516705 )
2018
48
Hypomethylation of the miRNA-34a gene promoter is associated with Severe Preeclampsia. ( 29557690 )
2018
49
MMP-14 aggravates onset of severe preeclampsia by mediating soluble endoglin release. ( 29565476 )
2018
50
High normal blood pressure in early pregnancy also contribute to early onset preeclampsia and severe preeclampsia. ( 29172803 )
2018

Variations for Severe Pre-Eclampsia

Expression for Severe Pre-Eclampsia

Search GEO for disease gene expression data for Severe Pre-Eclampsia.

Pathways for Severe Pre-Eclampsia

GO Terms for Severe Pre-Eclampsia

Cellular components related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 ADIPOQ ALB APLN APOH F5 LEP
2 collagen-containing extracellular matrix GO:0062023 9.56 ADIPOQ APOH MMP9 SERPINC1
3 extracellular region GO:0005576 9.47 ADIPOQ ALB APLN APOH F5 FGR
4 platelet alpha granule lumen GO:0031093 9.33 ALB F5 VEGFA

Biological processes related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.93 ADIPOQ APLN LEP PGF VEGFA
2 positive regulation of protein phosphorylation GO:0001934 9.8 ADIPOQ MMP9 PGF VEGFA
3 platelet degranulation GO:0002576 9.73 ALB APOH F5 VEGFA
4 response to ethanol GO:0045471 9.71 ADIPOQ LEP RBP4 VCAM1
5 glucose homeostasis GO:0042593 9.67 ADIPOQ LEP LEPR RBP4
6 lactation GO:0007595 9.65 APLN SERPINC1 VEGFA
7 leukocyte tethering or rolling GO:0050901 9.61 LEP VCAM1
8 macrophage differentiation GO:0030225 9.61 MMP9 VEGFA
9 vascular endothelial growth factor signaling pathway GO:0038084 9.6 PGF VEGFA
10 energy reserve metabolic process GO:0006112 9.59 LEP LEPR
11 negative regulation of gluconeogenesis GO:0045721 9.58 ADIPOQ LEPR
12 induction of positive chemotaxis GO:0050930 9.58 PGF VEGFA
13 regulation of blood coagulation GO:0030193 9.57 APOH SERPINC1
14 sexual reproduction GO:0019953 9.56 LEP LEPR
15 positive regulation of cold-induced thermogenesis GO:0120162 9.56 ADIPOQ LEP LEPR VEGFA
16 leptin-mediated signaling pathway GO:0033210 9.55 LEP LEPR
17 angiogenesis GO:0001525 9.55 APLN LEP LEPR PGF VEGFA
18 positive regulation of mast cell chemotaxis GO:0060754 9.52 PGF VEGFA
19 regulation of bone remodeling GO:0046850 9.51 LEP LEPR
20 negative regulation of vasoconstriction GO:0045906 9.46 APLN LEP
21 bone growth GO:0098868 9.32 LEP LEPR
22 response to nutrient GO:0007584 9.26 ADIPOQ LEP SERPINC1 VCAM1
23 response to hypoxia GO:0001666 9.02 ADIPOQ LEP PGF VCAM1 VEGFA

Molecular functions related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.8 ADIPOQ APLN HIF1AN HLA-G PGF VEGFA
2 signaling receptor binding GO:0005102 9.65 ADIPOQ APLN FGR HLA-G LEP
3 hormone activity GO:0005179 9.54 ADIPOQ APLN LEP
4 heparin binding GO:0008201 9.26 APOH PGF SERPINC1 VEGFA
5 identical protein binding GO:0042802 9.23 ADIPOQ ALB APOH HLA-G LEPR MMP9
6 vascular endothelial growth factor receptor 3 binding GO:0043185 9.16 PGF VEGFA

Sources for Severe Pre-Eclampsia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....